Can I read Section 5: Patient Safety and Quality Assurance - 5PSQ-062 Raltitrexed as an end-of-life treatment in patients with metastatic colorectal cancer on EtoBox?

Section 5: Patient Safety and Quality Assurance - 5PSQ-062 Raltitrexed as an end-of-life treatment in patients with metastatic colorectal cancer by Rodríguez Ferreras, A; Zapico García, I; Lázaro López, E; Ãlvarez Asteinza, C; Maray Mateos, I; Menárguez Blanc, R; Arias Martínez, A; Lozano Blázquez, A is a scholarly article available to read on EtoBox.

What is Section 5: Patient Safety and Quality Assurance - 5PSQ-062 Raltitrexed as an end-of-life treatment in patients with metastatic colorectal cancer about?

## Conclusion The heterozygous patients detected are at risk of developing severe toxicity when they are treated with fluoropyrimidines and they required a dose adjustment of these drugs. The use of these pharmacogenetic tools for the determination of polymorphisms of the DPYD gene in routine practice allows us to predict the potentially serious toxicity favouring the individualised use of these drugs.

Author

Rodríguez Ferreras, A; Zapico García, I; Lázaro López, E; Ãlvarez Asteinza, C; Maray Mateos, I; Menárguez Blanc, R; Arias Martínez, A; Lozano Blázquez, A

Publisher

British Medical Journal Publishing Group

Published

2019

Language

EN